191 related articles for article (PubMed ID: 25072363)
21. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects.
Undre NA; Stevenson P; Wilbraham D
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):237-44. PubMed ID: 24472403
[TBL] [Abstract][Full Text] [Related]
22. Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.
Chandra S; Fukuda T; Mizuno K; Davies SM; Teusink-Cross A; Tarin R; Marsh RA; Vinks AA; Mehta PA
J Antimicrob Chemother; 2018 Jun; 73(6):1651-1658. PubMed ID: 29481593
[TBL] [Abstract][Full Text] [Related]
23. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
[TBL] [Abstract][Full Text] [Related]
25. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
[TBL] [Abstract][Full Text] [Related]
26. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta P; Vinks A; Filipovich A; Vaughn G; Fearing D; Sper C; Davies S
Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González M; Carlos Montejo-González J
Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
[TBL] [Abstract][Full Text] [Related]
29. Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
Srinivas NR
Future Microbiol; 2016; 11(4):485-90. PubMed ID: 27070500
[TBL] [Abstract][Full Text] [Related]
30. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
[TBL] [Abstract][Full Text] [Related]
32. Micafungin use in children.
Emiroglu M
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
[TBL] [Abstract][Full Text] [Related]
33. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
Hope WW; Seibel NL; Schwartz CL; Arrieta A; Flynn P; Shad A; Albano E; Keirns JJ; Buell DN; Gumbo T; Drusano GL; Walsh TJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3714-9. PubMed ID: 17638696
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
Hope WW; Kaibara A; Roy M; Arrieta A; Azie N; Kovanda LL; Benjamin DK
Antimicrob Agents Chemother; 2015 Feb; 59(2):905-13. PubMed ID: 25421470
[TBL] [Abstract][Full Text] [Related]
37. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Hiramatsu Y; Maeda Y; Fujii N; Saito T; Nawa Y; Hara M; Yano T; Asakura S; Sunami K; Tabayashi T; Miyata A; Matsuoka KI; Shinagawa K; Ikeda K; Matsuo K; Tanimoto M;
Int J Hematol; 2008 Dec; 88(5):588-595. PubMed ID: 19039629
[TBL] [Abstract][Full Text] [Related]
38. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.
Cornely OA; Pappas PG; Young JA; Maddison P; Ullmann AJ
Expert Opin Drug Saf; 2011 Mar; 10(2):171-83. PubMed ID: 21306282
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
Seibel NL; Schwartz C; Arrieta A; Flynn P; Shad A; Albano E; Keirns J; Lau WM; Facklam DP; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2005 Aug; 49(8):3317-24. PubMed ID: 16048942
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of an elevated dosage of micafungin in premature neonates.
Smith PB; Walsh TJ; Hope W; Arrieta A; Takada A; Kovanda LL; Kearns GL; Kaufman D; Sawamoto T; Buell DN; Benjamin DK
Pediatr Infect Dis J; 2009 May; 28(5):412-5. PubMed ID: 19319022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
